Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR6 | P50406 | 2/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.42 |
| ▸ | HTR2C | P28335 | 8/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.39 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.39 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3786523 | 0.87 | CYP3A4 (0.50) | CHRNB2CHRNA4CYP3A4TSHRALDH1A1 | |
| SCHEMBL29769051 | 0.87 | CYP3A4 (0.50) | CHRNB2CHRNA4CYP3A4TSHRALDH1A1 | |
| SCHEMBL3786596 | 0.83 | CYP3A4 (0.46) | CHRNB2CHRNA4CYP3A4TSHRALDH1A1 | |
| SCHEMBL3784050 | 0.83 | CYP3A4 (0.46) | CHRNB2CHRNA4CYP3A4TSHRALDH1A1 | |
| SCHEMBL3385674 | 0.81 | SLC6A2 (0.52) | CHRNB2CHRNA4HTR1AHTR6SLC6A2 | |
| SCHEMBL3792360 | 0.81 | ALDH1A1 (0.46) | CHRNB2CHRNA4CYP3A4TSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL4886168 | 0.80 | SLC6A2 (0.51) | CHRNB2CHRNA4HTR1AHTR6SLC6A2 | |
| SCHEMBL12070785 | 0.79 | SLC6A2 (0.44) | CHRNB2CHRNA4HTR1AHTR6SLC6A2 | |
| SCHEMBL3386544 | 0.79 | SLC6A2 (0.52) | HTR1AHTR6SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL14320532 | 0.79 | HTR2C (0.58) | CHRNB2CHRNA4HTR1AHTR6SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| US-8071768-B2 | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA, N.V. (BE) | 2011-12-06 | — | — | US | disclosed |
| CN-101291922-A | Alkylquinoline and alkylquinazoline kinase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2008-10-22 | — | — | CN | disclosed |
| CN-101242845-A | Synergistic modulation of FLT3 kinase using a farnesyl transferase inhibitor | JANSSEN PHARMACEUTICA NV (BE) | 2008-08-13 | — | — | CN | disclosed |
| EP-1893214-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1893598-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-03-05 | — | — | EP | disclosed |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-01-04 | — | — | US | disclosed |
| WO-2006135629-A1 | SYNERGISTIC MODULATION OF FLT3 KINASE USING ALKYLQUINOLINES AND ALKYLQUINAZOLINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| WO-2006135721-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-12-21 | — | — | WO | disclosed |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2006-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | CHRNB2 4622/4885CHRNA4 4657/4885HTR1A 4450/4885 |
| US-20060281772-A1 | ALKYLQUINOLINE AND ALKYLQUINAZOLINE KINASE MODULATORS | FLT3, KIT, NTRK2 | CHRNB2 700/4885CHRNA4 662/4885HTR1A 773/4885 |
| US-20070004660-A1 | Synergistic Modulation of Flt3 Kinase Using Alkylquinolines and Alkylquinazolines | FLT3, MCL1, CDC42BPG | CHRNB2 3282/4885CHRNA4 3647/4885HTR1A 4634/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.